Losartan as a Steroid-Sparing Adjunct in a Patient With Features of Refractory Camurati-Engelmann Disease

Losartan as a Steroid-Sparing Adjunct in a Patient With Features of Refractory Camurati-Engelmann Disease

Objective: The treatment of Camurati-Engelmann disease (CED) involves the use of glucocorticoids, analgesics, and bisphosphonates; experience with the use of losartan is limited. Our objective was to describe the case of a patient diagnosed with CED whose symptoms remained refractory while on steroi...

Full description

Bibliographic Details
Main Authors: Khushboo Agarwal, MD, Remya Rajan, MD, Jinson Paul, MD, Kripa Elizabeth Cherian, MD, DM, DNB, Nitin Kapoor, MD, DM, PhD, Thomas V. Paul, MD, DNB, PhD
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:AACE Clinical Case Reports
Subjects:
bisphosphonates
Camurati-Engelmann disease
losartan
progressive diaphyseal dysplasia
steroids
TGFβ1
Online Access:http://www.sciencedirect.com/science/article/pii/S2376060521000912

Similar Items

Similar Items